Discover how Private Equity is transforming life sciences: revolutionizing R&D, redefining supply chains, and driving innovation for a healthier future Uncharted waters — this metaphor aptly describes today’s life sciences investment landscape. Private equity (PE) is a trailblazer, rewriting the rules with bold moves and strategic insights. It’s a realm where Platinum Equity’s acquisition of LifeScan symbolizes a strategic leap in digital health. This move, coupled with Blackstone, The Carlyle Group, and Hellman & Friedman’s transformative investment in Medline, marks a new epoch in medical supply innovation. Goldman Sachs’ bold 1.8 billion euros maneuver to acquire Norgine BV further cements PE’s influence in the sector. Over… […]
The post Gone with the Wind of PE: Life Sciences Sets Sail appeared first on DataDrivenInvestor.